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SUMMARY - Ectopic ACTH secretion was the first paraneoplastic endocrine syndrome described in
the literature. The most common tumors associated with ectopic ACTH production are small-cell lung
cancer and atypical carcinoids. High cortisol levels have also been described in patients with adenocar-
cinoma and large-cell carcinoma of the lung, other carcinoid tumors, thymoma, neural crest tumors,
medullary carcinoma of the thyroid, and bronchial adenomas. Patients rarely live long enough for frank
Cushing’s syndrome to develop. A 30-year-old male is described, who was admitted to endocrinology
ward for clinical features of Cushing’s syndrome. Outpatient examination showed high levels of plasma
cortisol on several occasions, without suppression of night dexamethasone test. Laboratory tests per-
formed during his hospital stay showed an increased level of serum cortisol without suppression of
night dexamethasone test, increased level of ACTH, and decreased testosterone level, increased 17 OHCS
in urine. CT scan of adrenal and pituitary glands, and chest x-ray were normal. The patient was dis-
charged with an appointment made for surgical exploration of the pituitary gland. Transnasal selective
partial hypophysectomy was performed, however, excisional biopsy showed no microadenoma while
the symptoms persisted postoperatively. The patient received TCT hypophysis in a maximal dose, and
elevated ACTH level was found to persist after 37 days of treatment. One year later, the patient was
readmitted for persistent cushinoid appearance. After complete investigations for ectopic ACTH se-
creting tumor, chest x-ray showed an infraclavicular, circular, sharply demarcated inhomogeneous le-
sion of the left lung, 2x3 cm in size. Three months later, lobectomy was performed and pathohistologic
examination pointed to a carcinoid (argentaffinoma). During hospitalization, the symptoms of Cushing’s
syndrome regressed. In conclusion, CRH test which usually distinguishes between hyperadrenocorti-
cism associated with ectopic ACTH secretion and hypersecreting adrenal tumors is sometimes mis-
leading because of the large overlap in normal and abnormal responses. In this case, chest or abdominal
CT scan or MRI should be performed, because these are the most common sites of ectopic ACTH
secreting tumors.
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Introduction
Ectopic adrenocorticotropic hormone (ACTH) secre-
tion was the first paraneoplastic endocrine syndrome de-
scribed in the literature. The most common tumors asso-
ciated with ectopic ACTH production are small-cell lung
cancer and atypical carcinoids. High cortisol levels have also
been described in patients with adenocarcinoma and large-
cell carcinoma of the lung, other carcinoid tumors, thy-
moma, neural crest tumors, medullary carcinoma of the
thyroid, and bronchial adenomas. Most patients have hy-
pokalemia and metabolic alkalosis. Patients rarely live long
enough for frank Cushing’s syndrome to develop. However,
diabetes, hypertensio, nedema, muscle wasting, central obe-
sity, moon facies, and striae may develop in those with ex-
tremely high cortisol levels. Diagnosis is confirmed by a
plasma ACTH level of more than 200 pg/mL, plasma cor-
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tisol level of more than 40 mg/dL without diurnal varia-
tion, or positive dexamethasone suppression test.
Several paraneoplastic syndromes are associated with
bronchogenic carcinoma. Sensitive and specific techniques
have enabled identification and serial measurement of a
variety of polypeptides and other physiologically active
substances secreted by these tumors, especially small-cell
cancers. Patients may become symptomatic from these
paraneoplastic disorders before their primary tumor be-
comes clinically apparent. For example, the onset of
Cushing’s syndrome or polymyositis in individuals who are
middle-aged or older should suggest the possible presence
of bronchogenic cancer. To some extent, tumor-produced
products (e.g., ACTH and HGH) can serve as biomarkers
of tumor activity.
Case Report
C.Z., a middle-aged (born 1956) driver from Karlovac,
married, two children, weight 75 kg, height 170 cm; at the
age of 30, admitted to the endocrinology ward for suspi-
cion of Cushing’s syndrome. The patient had been well
until a year before, when he experienced rounded (moon)
face, obesity, dryness of skin, decreased libido and impo-
tence, and echimosis after minimal trauma. Outpatient exa-
mination showed high plasma cortisol levels without sup-
pression of night dexamethasone test on several occasions.
Laboratory tests performed during his hospital stay
showed an increased level of serum cortisol (1181 nmol/L
at 8 a.m. and 1319 nmol/L at 5 p.m.) without suppression
of night dexamethasone test (654 nmol/L) and changed
rhythm of daily cortisol secretion, increased level of ACTH
(29.3 pmol/L at 8 a.m. and 45.5 pmol/L at 5 p.m.), de-
creased testosterone level (8.3 nmol/L), and increased 17
OHCS in urine (73.1 nmol/L) which persisted after four
days of dexamethasone test (72.1 nmol/L). Skull x-ray,
computed tomography (CT) scan of adrenal and pituitary
glands, and chest x-ray were normal. Laboratory tests for
Addison’s disease, performed because of the general hyper-
pigmentation of the skin, were negative.
The patient was discharged with an appointment for
surgical exploration of the pituitary gland, irrespective of
the CT scan results, because CT scan is known to only show
tumors larger than 2 mm, while those of less than 2 mm
cannot be visualized by CT but are usually detected on op-
eration.
Transnasal selective partial adenomectomy, performed
in Hamburg, did not show any microadenoma. Clinically,
the symptoms persisted postoperatively (serum cortisol
1380 and 1325 nmol/L at 8 a.m. and 5 p.m., respectively).
The patient was referred to nuclear medicine department
for postoperative radiotherapy and/or cyproheptadine for
suspicion of a suprasellar tumor, because ectopic ACTH
secretion was not proved, whole colonoscopy indicated
polyps, another chest x-ray and CT scan of the pituitary
were negative, and CT scan of the adrenal glands showed
mild hyperplasia.
The patient received TCT hypophysis in a maximal
dose of 8074 R and a focal dose of 4800 R with cyprohep-
tadine (Periactin, 3 tbl twice daily); after 37 daily treat-
ments, the ACTH level was still elevated (49.5 and 45.7
Fig. 1. Chest x-ray before operation Fig. 2. Chest x-ray after operation
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pmol/L at 8 a.m. and 5 p.m., respectively), and daily rhythm
of plasma cortisol was normal with a limited degree of sup-
pression after the use of dexamethasone (557 nmol/L).
One year later, the patient was readmitted for persistent
cushinoid appearance, buffalo hump, and skin striae. Hor-
monal tests showed increased serum cortisol (958 and 839
nmol/L at 8 a.m. and 5 p.m., respectively) and ACTH (48.8
and 44.6 pmol/L at 8 a.m. and 5 p.m., respectively), which
were not suppressed after 5-h infusion of dexamethasone
(618 nmol/L), while 750 mg Metopirone test (serum cor-
tisol 1005 and 483 nmol/L, and ACTH 33.3 and 66 pmol/
L at 8 a.m. and 5 p.m., respectively) and CRF test failed to
produce appropriate results. On repeated examination for
ectopic ACTH secreting tumor, chest x-ray showed an in-
fraclavicular, circular, sharply demarcated, inhomogeneous
lesion of the left lung, 2x3 cm in size. Three months later,
lobectomy was performed and pathohistologic examination
pointed to a carcinoid (argentaffinoma). Fig. 1, 2.
Postoperatively, the patient developed hypocortisolism,
probably due to the damage to basopilic cells by operation
and radiation, and prolonged suppression of the paraendo-
crine secretion of ACTH from pulmonary carcinoid. X-ray
of the thorax and abdomen showed no metastases. During
hospital stay, the symptoms of Cushing’s syndrome re-
gressed, however, there was persistent hypokalemia (2.6
mEq/L; normal 4.1-5.0 mE1/L), which was explained as
a nutritive deficiency due to the decreased serum and urine
levels of aldosterone (69 pmol/L and 1 nmol/dU, respec-
tively) and cortisol.
Methods
The level of serum cortisol was determined by the stan-
dard radioimmunoassay (RIA) method allowing exact cor-
tisol concentration to be measured in a small serum volume.
125I labeled hormne was used. Both 125I-cortisol and un-
labeled serum cortisol bind to specific antibody according
to their concentration in the radioactive mixture. The
amount of 125I-cortisol binding to the antibody is reversely
reciprocal to the concentration of unlabeled serum corti-
sol.
Venous blood samples of 5 mL were obtained in the
morning (8 a.m.) and afternoon (5 p.m.) after 30-min bed
rest. In a healthy person, the cortisol secretion rate is higher
in the morning (6-8 a.m.) and lower in the evening (4-6
p.m.), due to the cyclic hypothalamic secretion of CRF. At
our laboratory, normal cortisol values are 138-800 nmol/L
at 8 a.m. and 50%-70% of the morning values at 5 p.m.
In dexamethasone suppression test performed at bed-
time (11 p.m.), two 0.5-mg dexamethasone tablets were
administered per os. Venous blood samples were obtained
at 8 a.m. and 5 p.m. on the day following the administra-
tion of dexamethasone. Normal cortisol values are less than
80 nmol/L.
Urinary cortisol excretion in 24-h collection is the most
useful test. It has a better specificity than the overnight 1-
mg dexamethasone suppression test and escapes various
pitfalls pertaining to dexamethasone metabolism and drug
interference.
Skull x-ray will often show evidence of osteopenia of
the dorsum sellae, and provide the neurosurgeon with useful
indications on the bone landmarks and state of pneumati-
zation of the sphenoidal sinus.
CT scanning has for a long time been the only imag-
ing technique for the pituitary gland. CT can achieve a
sensitivity no higher than 50%. A microadenoma will ap-
pear as a hypodense round lesion; the mass effect on the
pituitary stalk and diaphragm will depend on the size of the
lesion. The specificity of CT is not perfect, since abnormal
images are not infrequent and may provide false-positive
results in patients with other causes of Cushing’s syndrome.
Magnetic resonance imaging (MRI) without and with
gadolinium enhancement has significantly improved the
ability to detect pituitary microadenomas in Cushing’s dis-
ease. Several studies have shown that many patients with a
negative CT have a positive MRI finding. A hypointense
signal that is better detectable upon enhancement is typi-
cal of microadenoma.
Discussion
ACTH-dependent hyperfunction of the adrenal gland
cortex may occur due to hypersecretion of ACTH by the
pituitary, secretion of ACTH by a non-pituitary tumor such
a small-cell carcinoma of the lung (ectopic ACTH syn-
drome), or administration of exogenous ACTH. Patients
with Cushing’s disease may have a basophilic adenoma of
the pituitary or a chromophobe adenoma. Microadenomas
can usually be visualized by CT or preferably MRI scan,
using high resolution technique enhanced by gadolinium.
Some microadenomas are difficult to visualize even with
these modalities. In some cases, no histologic abnormality
is found in the pituitary despite clear evidence of ACTH
overproduction.
Plasma cortisol is normally 5-25 mg/dL in the early
morning (6-8 a.m.), and declines gradually to less than 10
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mg/dL in the evening (6 p.m. and after). Patients with
Cushing’s syndrome usually have elevated morning corti-
sol levels and lack of the normal diurnal decline in cortisol
production, so that evening plasma cortisol levels are above
normal and total 24-h cortisol production is increased. Free
urinary cortisol, the best assay for urinary excretion, is el-
evated in Cushing’s patients and is subject to only minimal
increase in obese patients (normal 20 to 10 mg/24 h). Per-
oral administration of 1 mg dexamethasone at 11-12 p.m.
with plasma cortisol measurement at 7-8 a.m. on the next
morning has been used as a screening test for Cushing’s
snydrome. In patients with adrenal tumors, cortisol produc-
tion is independent of ACTH and therefore dexametha-
sone will have no suppression effect. In patients with the
ectopic ACTH syndrome, the production of ACTH by a
non-pituitary tumor is almost always unaffected by dexam-
ethasone; hence, urinary steroids remain unchanged.
The CRH test usually distinguishes between hypera-
drenocorticism associated with ectopic ACTH secretion
and hypersecretion from adrenal tumors in which no re-
sponse occurs, and the pituitary form of Cushing’s disease
in which the response is normal or enhanced. However, this
test is sometimes misleading because of a large overlap in
normal and abnormal reponses. It is most valuable when
combined with a positive dexamethasone suppression test.
When the pituitary is the source of excessive ACTH
secretion, the standard approach is to perform a trans-sphe-
noidal exploration of the pituitary and excise the tumor if
one is found. If no tumor is found, some physicians pro-
ceed to hypophysectomy, but most believe that the next step
is supervoltage irradiation of the pituitary, delivering 4000
to 5000 R. In special centers, heavy particle beam irradia-
tion, providing about 10 000 R, is also often successful.
Response to irradiation may require several months.
Adrenocortical neoplasms are surgically removed. Pa-
tients must receive supplementary cortisol intra- and post-
operatively, since their non-tumorous adrenal cortex will be
atrophic and suppressed. Where possible, the treatment for
ectopic ACTH syndrome consists of removing the non-
pituitary tumor producing ACTH. However, in most cases
the tumor is disseminated and cannot be excised.
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Saæetak
PRIKAZ BOLESNIKA S EKTOPI»NOM SEKRECIJOM ACTH I ZNACIMA CUSHINGOVA SINDROMA
M. Vrkljan, B. Vizner, A. Zawawi, M. BekiÊ, M. GoreÊan i I. Grbac
Prvi paraneoplastiËni endokrini sindrom opisan u literaturi bila je ektopiËna sekrecija  ACTH. NajËe¹Êi tumori udruæeni s
ektopiËnom sekrecijom ACTH su mikrocelularni karcinom pluÊa i atipiËni karcinoidi. Visoke razine kortizola opisane su i u
bolesnika s adenokarcinomom i karcinomom velikih stanica pluÊa, karcinoidima, timomom, tumorima neuralnog grebena, me-
dularnim karcinomom ¹titnjaËe i bronhalnim adenomom. Bolesnici rijetko æive dovoljno dugo da razviju manifestan Cushingov
sindrom. Opisan je sluËaj 30-godi¹njeg mu¹karca koji je primljen na odjel s kliniËim znacima Cushingova sindroma. Ambulantno
ispitivanje pokazalo je u vi¹e navrata visoke razine kortizola koji se nije sniæavao u kratkom deksametazonskom testu. Tijekom
boravka u bolnici je uz veÊ navedeno uoËena visoka razina ACTH, sniæeni testosteron i povi¹en 17 OHCS u mokraÊi. CT
nadbubreæenih ælijezda i Rtg snimka prsnog ko¹a bili su uredni. Bolesnik je otpu¹ten uz dogovor za kirur¹ku eksploraciju hipofize,
te je uËinjena transnazalna djelomiËna hipofizektomija. Ekscizijska biopsija nije pokazala znakove tumora, a kliniËki znaci Cushingova
sindroma ustrajali su nakon operacije. Bolesnik je podvrgnut radioterapiji hipofize u maksimalnoj dozi, meðutim, vrijednosti
ACTH su jo¹ uvijek bile povi¹ene. Nakon godinu dana bolesnik je ponovno primljen na odjel zbog ustrajnih znakova Cushingova
sindroma. Nakon potpune obrade u smislu traæenja ektopiËne sekrecije ACTH, snimka prsnoga ko¹a pokazala je infraklavikularno
o¹tro ograniËenu, nehomogenu sjenu u pluÊima, veliËine 2x3 cm. Tri mjeseca kasnije uËinjena je lobektomija, a patohistolo¹ki nalaz
je ukazao na karcinoid (argentafinom). Tijekom hospitalizacije simptomi Cushingova sindroma su se povukli. U zakljuËku, CRH
test koji obiËno razlikuje hiperadrenokorticizam udruæen s ektopiËnom sekrecijom ACTH i hipersekreciju iz adrenalnih tumora,
ponekad je neprikladan zbog znaËajnog preklapanja u normalnom i abnormalnom odgovoru. U tom sluËaju, nuæan je detaljan
pregled prsnoga ko¹a i trbuha, buduÊi da su to najËe¹Êa sijela tumora koji ektopiËno izluËuju ACTH.
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